Biosimilars in the United States: Ready, Set, Launch

Webinar Recorded on April 29, 2015 

Click here to download PDF of presentation

This webinar provides the latest information on biosimilar launches in the United States and the updates on key regulatory issues affecting market uptake, including the impact of naming issues on market uptake, status of FDA interchangeability guidance, and state action on pharmacists' ability to substitute interchangeable biosimilars. This webinar features an expert from the Federal Trade Commission who discuss the latest activity and also analysts who will findings from survey examining pharmacists' confidence in substituting interchangeable biosimilars based on naming conventions.

Speakers:

Elizabeth Jex, JD
Attorney Advisor, Office of Policy Planning, Federal Trade Commission

Sara Fernandez-Lopex, PhD, MBA, 
Director, Reimbursement Strategy, Xcenda,

Denise Kazzaz, BA
Director,Scientific Client Strategies, Xcenda